BELLICUM PHARMACEUTICALS, INC
Form 424B5
October 05, 2018
Table of Contents

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-226652

PROSPECTUS SUPPLEMENT

(To Prospectus dated August 23, 2018)

$60,000,000

Common Stock

We have entered into an Open Market Sale Agreement[SM], or sales agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock, from time to time, having an aggregate offering price of up to $60.0 million through Jefferies acting as sales agent.

Our common stock is traded on The Nasdaq Global Market under the symbol BLCM. On October 3, 2018, the last reported sale price of our common stock was $6.35 per share.

Sales of our shares, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be an at the market offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Jefferies is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Jefferies and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

Jefferies will be entitled to compensation under the terms of the sales agreement at a fixed commission rate of up to 3.0% of the gross sales price per share sold under the sales agreement. See Plan of Distribution beginning on page S-11 for additional information regarding Jefferies compensation. In connection with the sale of common stock on our behalf, Jefferies will be deemed to be an underwriter within the meaning of the Securities Act and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification to Jefferies against certain liabilities, including liabilities under the Securities Act.

Investing in our common stock involves risks. See Risk Factors beginning on page S-7.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this prospectus supplement or the accompanying prospectus are truthful or complete. Any representation to the contrary is a criminal offense.

Jefferies

October 5, 2018

Table of Contents

TABLE OF CONTENTS

Prospectus Supplement

Prospectus

Table of Contents

ABOUT THIS PROSPECTUS SUPPLEMENT

This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of common stock and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus dated August 23, 2018, including the documents incorporated by reference therein, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference that was filed with the Securities and Exchange Commission, or SEC, before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date for example, a document incorporated by reference in the accompanying prospectus the statement in the document having the later date modifies or supersedes the earlier statement.

We have not, and Jefferies has not, authorized anyone to provide you with information different than or inconsistent with the information contained in or incorporated by reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we have authorized for use in connection with this offering. We and Jefferies take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are not, and Jefferies is not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents, regardless of the time of delivery of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the section of this prospectus supplement entitled Incorporation of Certain Information by Reference.

We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of our common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of our common stock and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.

Unless otherwise stated, all references in this prospectus to we, us, our, Bellicum, Bellicum Pharmaceuticals, the Company and similar designations refer to Bellicum Pharmaceuticals, Inc. and its subsidiaries on a consolidated basis. This prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein contain common law, unregistered trademarks for Bellicum Pharmaceuticals based on use of the trademarks in the United States. Other trademarks referred to in this prospectus supplement or the accompanying prospectus or the information incorporated by reference herein and therein are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this prospectus supplement, the accompanying prospectus and

the information incorporated by reference herein and therein, including logos, artwork and other visual displays, may appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Table of Contents

Notice to Prospective Investors in the European Economic Area

This prospectus supplement and the accompanying prospectus are not prospectuses for the purpose of the Prospectus Directive (as defined below). This prospectus supplement and the accompanying prospectus have been prepared on the basis that any offer of shares in any Member State of the European Economic Area (the EEA) which has implemented the Prospectus Directive (each, a Relevant Member State) will only be made to a legal entity which is a qualified investor under the Prospectus Directive (Qualified Investors). Accordingly any person making or intending to make an offer in that Relevant Member State of shares which are the subject of the offering contemplated in this prospectus supplement and the accompanying prospectus may only do so with respect to Qualified Investors. Neither we nor Jefferies have authorized, nor do we or Jefferies authorize, the making of any offer of shares other than to Qualified Investors. The expression Prospectus Directive means Directive 2003/71/EC (as amended, including by Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant Member State.

MIFID II Product Governance

Any distributor subject to Directive 2014/65/EU, as amended (MiFID II) that is offering, selling or recommending the shares of common stock is responsible for undertaking its own target market assessment in respect of the shares of common stock and determining its own distribution channels for the purposes of the MiFID II product governance rules under Commission Delegated Directive (EU) 2017/593 (Delegated Directive). Neither we nor Jefferies make any representations or warranties as to a distributor s compliance with the Delegated Directive.

Notice to Prospective Investors in the United Kingdom

The communication of this prospectus supplement, the accompanying prospectus and any other document or materials relating to the issue of the shares offered hereby is not being made, and such documents and/or materials have not been approved, by an authorized person for the purposes of section 21 of the United Kingdom s Financial Services and Markets Act 2000, as amended. Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion is only being made to those persons in the United Kingdom falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Financial Promotion Order)), or within Article 49(2)(a) to (d) of the Financial Promotion Order, or to any other persons to whom it may otherwise lawfully be made under the Financial Promotion Order (all such persons together being referred to as relevant persons). In the United Kingdom, the shares offered hereby are only available to, and any investment or investment activity to which this prospectus supplement and the accompanying prospectus relate will be engaged in only with, relevant persons. Any person in the United Kingdom that is not a relevant person should not act or rely on this prospectus supplement or the accompanying prospectus or any of their contents.

Table of Contents

FORWARD-LOOKING STATEMENTS

This prospectus supplement, the accompanying prospectus, the documents incorporated by reference and any free writing prospectus that we have authorized for use in connection with this offering contain forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the safe harbor created by those sections. We may, in some cases, use words such as anticipate, believe, could, estimate, expect, intend, may, plan, potential, predict, will, would or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements may include, but are not limited to, statements about:

- the success, cost and timing of our product development activities and clinical trials;
- our ability to advance Chemical Induction of Dimerization, or CID, CID-based technologies, including CaspaCIDe and GoCAR-T;
- our ability to obtain and maintain regulatory approval of BPX-501 and any other product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate;
- our ability to successfully maintain our internal manufacturing operations;
- our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates;
- the commercialization of our product candidates, if approved;
- our plans to research, develop and commercialize our product candidates;
- our ability to attract collaborators with development, regulatory and commercialization expertise and the success of any such collaborations;
- future agreements with third parties in connection with the commercialization of our product candidates and any other approved product;
- the size and growth potential of the markets for our product candidates, and our ability to serve those markets;

the rate and degree of market acceptance of our product candidates;

regulatory developments in the United States, or U.S., and foreign countries;

our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

the success of competing therapies that are or may become available;

our ability to attract and retain key scientific or management personnel;

our ability to grow our organization and increase the size of our facilities to meet our anticipated growth;

the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

our expectations regarding the period during which we qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act;

our use of cash and other resources, including the use of proceeds from this offering; and

our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates.

These forward-looking statements reflect our management s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this prospectus supplement and are subject to risks and uncertainties. We discuss many of these risks in greater detail under Risk Factors. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

Table of Contents

You should read this prospectus supplement and the accompanying prospectus together with the documents that we have filed with the SEC that are incorporated by reference and any free writing prospectus we have authorized for use in connection with a specific offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus supplement by these cautionary statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Table of Contents

PROSPECTUS SUPPLEMENT SUMMARY

This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference into this prospectus supplement. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of our company and this offering, you should read and consider carefully the more detailed information included or incorporated by reference in this prospectus supplement and the accompanying prospectus, including the risks described under the heading Risk Factors, as well as the information included in any free writing prospectus that we have authorized for use in connection with this offering.

Overview

We are a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. We are using our proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer our product candidates with switch technologies that are designed to control components of the immune system in real time. By incorporating our CID platform, our product candidates may offer better safety and efficacy outcomes than are seen with current cellular immunotherapies.

We are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including chimeric antigen receptor T cell therapy, or CAR T, T cell receptors, or TCRs and hematopoietic stem cell transplantation, or HSCT. CAR T and TCR cell therapies are an innovative approach in which a patient s T cells are genetically modified to carry chimeric antigen receptors, or CARs, or TCRs which redirect the T cells against cancer cells. While high objective response rates have been reported in some hematological malignancies, serious and sometimes fatal toxicities have arisen in patients treated with CAR T cell therapies. These toxicities include instances in which the CAR T cells have caused high levels of cytokines due to over-activation, referred to as cytokine release syndrome, or CRS, neurologic toxicities and cases in which CAR T cells have attacked healthy organs. In each case, these toxicities have sometimes resulted in death. In solid tumors, where the behavior of CAR T cells is particularly unpredictable and results have been inconsistent, researchers are developing enhanced CAR T cell approaches that raise even greater safety concerns. HSCT, also known as bone marrow transplantation, has for decades been curative for many patients with hematological cancers or orphan inherited blood disorders. However, adoption of HSCT to date has been limited by the risks of transplant-related morbidity and mortality from graft-versus-host-disease, or GvHD, and the potential for serious infections or cancer recurrence due to the lack of an effective immune system following a transplant.

Our proprietary CID platform is designed to address these challenges. Events inside a cell are controlled by cascades of specialized signaling proteins. CID consists of molecular switches, modified forms of these signaling proteins, which are triggered inside the patient by infusion of a small molecule, rimiducid, instead of by natural upstream signals. We include these molecular switches in the appropriate immune cells and deliver the cells to the patient in the manner of conventional cellular immunotherapy. We have developed two such switches: a safety switch, designed to initiate programmed cell death, or apoptosis, of the immunotherapy cells, and an activation switch, designed to stimulate activation and in some cases proliferation and/or persistence of the immunotherapy cells. Each of our product candidates incorporates one of these switches, for enhanced, real time control of safety and efficacy:

- CaspaCIDe (also known as inducible Caspase-9, or iC9) is our safety switch, incorporated into our HSCT and TCR product candidates, and into academic CAR T collaborations, where it is inactive unless the patient

experiences a serious side effect. In that event, rimiducid is administered to induce Caspase-9 and eliminate a majority of the cells, with the goal of attenuating the therapy and resolving the serious side effect.

Table of Contents

Our activation switch (also known as inducible MyD88/CD40, or iMC) incorporated into our GoCAR-T product candidates is designed to enable control of the activation and proliferation of the T cells through the scheduled administration of a course of rimiducid infusions that may continue until the desired patient outcome is achieved. In the event of emergence of side effects, the level of activation of the GoCAR-T cells is designed to be attenuated by extending the interval between rimiducid doses, reducing the dosage per infusion, or suspending further rimiducid administration.

In addition, we have an active research effort to develop other advanced molecular switch approaches, including a dual-switch GoCAR-T that is designed to provide a user-controlled system for managing proliferation and/or persistence and safety of tumor antigen-specific CAR T cells.

By incorporating our novel switch technologies, we are developing product candidates with the potential to elicit positive clinical outcomes and ultimately change the treatment paradigm in various areas of cellular immunotherapy. Our clinical product candidates are described below.

BPX-501 is a CaspaCIDe product candidate designed as an adjunct polyclonal T cell therapy administered after allogeneic HSCT. BPX-501 is designed to improve transplant outcomes by enhancing the recovery of the immune system following an HSCT procedure, thereby preventing serious infections and leukemic relapse, two leading causes of morbidity and mortality in these patients. BPX-501 addresses the risk of infusing donor T cells by enabling the elimination of donor T cells through the activation of the CaspaCIDe safety switch if there is an emergence of uncontrolled GvHD.

The European Commission has granted orphan drug designations to BPX-501 for treatment in HSCT, and for activator agent rimiducid for the treatment of GvHD. Additionally, BPX-501 and rimiducid have received orphan drug status from the U.S. Food and Drug Administration, or the FDA, as a combination replacement T-cell therapy for the treatment of immunodeficiency and GvHD after allogeneic HSCT.

Based on interactions with the European Medicines Agency, or the EMA, we believe that data from the European arm of our BP-004 trial could form the basis of marketing authorization applications, or MAAs, for BPX-501 and rimiducid for pediatric patients with certain orphan inherited blood disorders or treatment-refractory hematological cancers. In addition, the EMA s Committee for Medicinal Products for Human Use, or the CHMP, has agreed that review and approval under exceptional circumstances may be suitable, recognizing that a randomized trial may not be feasible in the pediatric haploidentical hematopoietic stem cell transplant setting. In place of a randomized trial, we are collecting data from the C-004 study, a concurrent observational study in the pediatric matched unrelated donor hematopoietic stem cell transplant setting, which includes both retrospective patients and prospective patients. We expect to report updated interim results from the European BP-004 clinical trial in the fourth quarter of 2018 and to file MAAs for European marketing approvals in 2019.

We are currently planning an additional clinical trial for BPX-50l. We are designing a randomized, controlled trial in adults with acute myeloid leukemia or myelodysplastic syndromes to compare outcomes in patients receiving a haplo-transplant with and without BPX-501.We expect to initiate this clinical trial by the end of 2018.

BPX-601 is a GoCAR-T product candidate containing our proprietary inducible MyD88/CD40, or iMC, activation switch, designed to treat solid tumors expressing prostate stem cell antigen, or PSCA. Preclinical data shows enhanced T cell proliferation, persistence and in vivo anti-tumor activity compared to traditional

CAR T therapies. A Phase 1 clinical trial in patients with non-resectable pancreatic cancer is ongoing and we expect to report initial data from this clinical trial in the fourth quarter of 2018. In addition to pancreatic cancer, PSCA is expressed in several other solid tumor indications. We modified the ongoing Phase 1 protocol to include prostate and gastric cancer patients in the third quarter of 2018, and expect to add additional clinical trial sites in the second half of 2018.

Table of Contents

BPX-701 is a CaspaCIDe-enabled natural high affinity TCR product candidate designed to target malignant cells expressing the preferentially-expressed antigen in melanoma, or PRAME. The ongoing Phase 1 clinical trial for BPX-701 is in adult patients with refractory or relapsed acute myeloid leukemia, or AML, and myelodysplastic syndromes, or MDS. Recruitment in this clinical trial has been slower than projected and we are working to address this by adding clinical trial sites. We expect to report initial data from this clinical trial in 2019.

CD19 CAR T Program We are working with academic collaborators to establish clinical proof of concept for CaspaCIDe® in the CD19-expressing B cell malignancies setting. We believe that this strategy allows a cost-effective approach for clinical evaluation of CaspaCIDe in attenuating the acute toxicities of CD19-targeted therapies. In November 2016 we announced an expanded collaboration with Ospedale Pediatrico Bambino Gesù, or OPBG, a leading European pediatric research center and hospital, where clinical development of a CaspaCIDe-enabled CD19 CAR T cell therapy is ongoing. As of June 15, 2018, six patients had been dosed in the CD19 clinical trial at OPBG without yet an incident of toxicities for which the CaspaCIDe® safety switch has been used.

We have developed efficient and scalable processes to manufacture genetically modified T cells of high quality, which are currently being used to produce BPX-501, BPX-601 and BPX-701 for our clinical trials. We are leveraging this know how in combination with our proprietary cellular control technologies, resources, capabilities and expertise for the manufacture of CAR T and TCR product candidates to create and develop first and best-in-class product candidates.

We have established in-house cell manufacturing and vector production capabilities at our headquarters facility in Houston, Texas. In the first quarter of 2017, the initial phase of the build-out was completed and we began manufacturing clinical trial material from this site. We completed the facility build-out in early 2018, and we expect that our facilities will meet our U.S. clinical trial and early commercialization requirements. For the European market, we plan to continue working with established contract manufacturers, with our U.S. manufacturing facility as a potential backup supply source.

Corporate Information

We were incorporated in Delaware in July 2004. Our principal offices are located at 2130 W. Holcombe Blvd., Ste. 800, Houston, Texas and our telephone number is (832) 384-1100. Our corporate website address is www.bellicum.com. The contents of our website are not a part of, and are not incorporated into, this prospectus supplement or the accompanying prospectus, and you should not consider it part of this prospectus supplement or the accompanying prospectus and you should not rely on any such information in making any decisions of whether to purchase our securities. For further information regarding us and our financial information, you should refer to our recent filings with the SEC. See Incorporation of Certain Information by Reference.

Table of Contents

THE OFFERING

Issuer	Bellicum Pharmaceuticals, Inc.
Common stock offered by us	Shares of our common stock having an aggregate offering price of up to $60.0 million
Common stock to be outstanding after this offering	52,795,038 shares (as more fully described in the notes following this table)
Manner of offering	At-the-market offering that may be made from time to time through our sales agent, Jefferies. See Plan of Distribution.
Use of proceeds	We currently intend to use the net proceeds, if any, from this offering to fund clinical development and other research and development activities and for working capital and general corporate purposes. See Use of Proceeds.
Risk factors	Investing in our common stock involves a high degree of risk. See Risk Factors for a discussion of factors that you should consider before buying shares of our common stock.
Symbol on The Nasdaq Global Market	BLCM

The number of shares of common stock to be outstanding after this offering as shown in the table above assumes for illustrative purposes that an aggregate 9,448,818 shares of our common stock are sold at a price of $6.35 per share, the last reported sale price of our common stock on The Nasdaq Global Market on October 3, 2018, for aggregate gross proceeds of $60.0 million, and is based on 43,346,220 shares outstanding as of June 30, 2018. The number of shares of common stock to be outstanding after this offering will adjust based on the actual number of shares that we sell in this offering. In addition, the number of shares of our common stock outstanding as of June 30, 2018 excludes the following:

- 5,265,521 shares of common stock issuable upon the exercise of outstanding stock options as of June 30, 2018, at a weighted-average exercise price of $12.67 per share of common stock;
- 217,186 shares of common stock issuable upon the vesting of outstanding restricted stock units as of June 30, 2018;

14,707 shares of common stock subject to repurchase by us as of June 30, 2018;

2,498,102 shares of common stock reserved for future issuance under our 2014 Equity Incentive Plan, as of June 30, 2018; and

446,248 shares of common stock reserved for future issuance under our 2014 Employee Stock Purchase Plan, as of June 30, 2018.

Except as otherwise noted, all information in this prospectus supplement assumes no exercise of the underwriters option to purchase additional shares and no exercise of the outstanding stock options described above.

Table of Contents

RISK FACTORS

Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, those contained in the section entitled Risk Factors in our Quarterly Report on Form 10-Q for the period ended June 30, 2018, which are incorporated herein by reference in their entirety, as well as any amendment or update to our risk factors reflected in subsequent filings with the SEC, all other information in this prospectus supplement, the accompanying prospectus, and the other documents incorporated by reference, and in any free writing prospectus that we have authorized for use in connection with this offering. The risks described in these documents are not the only ones we face, but those that we consider to be material. The occurrence of any of these risks could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.

Risks Relating to this Offering

If you purchase shares of common stock in this offering, you will experience immediate and substantial dilution in your investment. You will experience further dilution if we issue additional equity or equity-linked securities in the future.

Since the price per share of our common stock being offered may be substantially higher than the net tangible book value per share of our common stock, you may suffer immediate and substantial dilution with respect to the net tangible book value of the common stock you purchase in this offering. The shares sold in this offering, if any, will be sold from time to time at various prices. After giving effect to the sale of our common stock in the maximum aggregate offering amount of $60.0 million at an assumed offering price of $6.35 per share, and our net tangible book value as of June 30, 2018, if you purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of $3.11 per share with respect to the net tangible book value of the common stock. See the section entitled Dilution for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering.

If we issue additional shares of common stock, or securities convertible into or exchangeable or exercisable for shares of common stock, our stockholders, including investors who purchase shares of common stock in this offering, will experience additional dilution, and any such issuances may result in downward pressure on the price of our common stock. We also cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders.

We will have broad discretion in the use of the net proceeds from this offering and may not use them effectively.

We will have broad discretion in the use of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. Our failure to apply these funds effectively could have a material adverse effect on our business, impair or delay our ability to develop our product candidates and cause the price of our common stock to decline. See the section entitled Use of Proceeds.

The actual number of shares we will issue under the sales agreement, at any one time or in total, is uncertain.

Subject to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement notice to Jefferies at any time throughout the term of the sales agreement. The number of shares that are sold by Jefferies after delivering a placement notice will fluctuate based on the market price of our common

stock during the sales period and limits we set with Jefferies. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this time to predict the number of shares that will ultimately be issued.

Table of Contents

USE OF PROCEEDS

The amount of the net proceeds to us from this offering will depend upon the number of shares of our common stock sold and the price at which they are sold. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with Jefferies.

We currently intend to use the net proceeds, if any, from this offering to fund clinical development and other research and development activities and for working capital and general corporate purposes. Amounts and timing of our actual expenditures will depend on numerous factors, including the timing and progress of our clinical trial and research and development efforts. We therefore cannot estimate with certainty the amount of net proceeds to be used for the purposes described above. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds.

Pending their use as described above, we plan to invest the net proceeds from this offering in short-and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.

Table of Contents

DILUTION

Our net tangible book value as of June 30, 2018 was approximately $112.5 million, or $2.60 per share. Net tangible book value per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of June 30, 2018. Dilution with respect to net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering.

After giving effect to the sale of $60.0 million of our common stock in this offering at the assumed public offering price of $6.35 per share, which is the last reported sale price of our common stock on The Nasdaq Global Market on October 3, 2018, and after deducting offering commissions and estimated expenses payable by us, our as adjusted net tangible book value as of June 30, 2018 would have been approximately $170.9 million, or $3.24 per share. This represents an immediate increase in net tangible book value of $0.64 per share to existing stockholders and immediate dilution in net tangible book value of $3.11 per share to new investors purchasing our common stock in this offering. The following table illustrates this dilution on a per share basis:

Assumed public offering price per share		$ 6.35
Net tangible book value per share as of June 30, 2018	$ 2.60	
Increase in net tangible book value per share attributable to investors purchasing our common stock in this offering	$ 0.64	
As adjusted net tangible book value per share as of June 30, 2018 after this offering		$ 3.24
Dilution per share to investors purchasing our common stock in this offering		$ 3.11

The table above assumes for illustrative purposes that an aggregate 9,448,818 shares of our common stock are sold at a price of $6.35 per share, which is the last reported sale price of our common stock on The Nasdaq Global Market on October 3, 2018, for aggregate gross proceeds of $60.0 million. The shares sold in this offering, if any, will be sold from time to time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed public offering price of $6.35 per share shown in the table above, assuming all of our common stock in the aggregate amount of $60.0 million is sold at that price, would increase our as adjusted net tangible book value per share after the offering to approximately $3.32 per share and would increase the dilution in net tangible book value per share to new investors in this offering to approximately $4.03 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed public offering price of $6.35 per share shown in the table above, assuming all of our common stock in the aggregate amount of $60.0 million is sold at that price, would decrease our as adjusted net tangible book value per share after the offering to $3.13 per share and would decrease the dilution in net tangible book value per share to new investors in this offering to $2.22 per share, after deducting commissions and estimated aggregate offering expenses payable by us.

The number of shares of common stock to be outstanding after this offering will adjust based on the actual number of shares that we sell in this offering. In addition, the number of shares of our common stock outstanding as of June 30, 2018 excludes the following:

- 5,265,521 shares of common stock issuable upon the exercise of outstanding stock options as of June 30, 2018, at a weighted-average exercise price of $12.67 per share of common stock;
- 217,186 shares of common stock issuable upon the vesting of outstanding restricted stock units as of June 30, 2018;
- 14,707 shares of common stock subject to repurchase by us as of June 30, 2018;
- 2,498,102 shares of common stock reserved for future issuance under our 2014 Equity Incentive Plan, as of June 30, 2018; and
- 446,248 shares of common stock reserved for future issuance under our 2014 Employee Stock Purchase Plan, as of June 30, 2018.

Table of Contents

To the extent that outstanding options are exercised, investors purchasing our common stock in this offering will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.

Table of Contents

PLAN OF DISTRIBUTION

We have entered into an Open Market Sale Agreement℠, or sales agreement, with Jefferies, under which we may issue and sell from time to time up to $60.0 million of our shares of common stock through the sales agent. The sales agreement has been filed as an exhibit to a Current Report on Form 8-K filed under the Exchange Act and is incorporated by reference in this prospectus supplement. Sales of our shares, if any, under this prospectus supplement may be made in sales deemed to be at the market offerings as defined in Rule 415 under the Securities Act, including by means of ordinary brokers transactions on The Nasdaq Global Market at market prices, in privately negotiated transactions, block transactions, or as otherwise agreed upon by the sales agent and us. The sales agent will use commercially reasonable efforts to sell on our behalf all of the shares requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between the sales agent and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

The sales agent will offer the shares subject to the terms and conditions of the sales agreement on any trading day or as otherwise agreed upon by us and the sales agent. We will designate the maximum amount and minimum price of shares to be sold through the sales agent, which may be on a daily basis or otherwise determine such amounts together with the sales agent. Subject to the terms and conditions of the sales agreement, the sales agent will use its commercially reasonable efforts to sell on our behalf the shares. We may instruct the sales agent not to sell shares if the sales cannot be effected at or above the price designated by us in any such instruction. We or the sales agent may suspend the offering of shares being made through the sales agent under the sales agreement upon proper notice to the other party.

Under the terms of the sales agreement, the sales agent will receive from us a commission of up to 3.0% of the gross proceeds of any shares sold through it pursuant to the sales agreement. The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such shares.

The sales agent will provide written confirmation to us before the open of trading on The Nasdaq Global Market on the day following each day in which shares are sold by the sales agent for us under the sales agreement. Each confirmation will include the number of shares sold on that day, the gross sales price per share, and the net proceeds to us.

Settlement for sales of shares will occur, unless the parties agree otherwise, on the second business day following the date on which any sales were made in return for payment of the net proceeds to us.

If we and Jefferies so agree, Jefferies may act as principal in connection with the placement of the securities offered hereby. In connection with the sale of the shares on our behalf, the sales agent will be deemed to be an underwriter within the meaning of the Securities Act and the compensation paid to the sales agent will be deemed to be underwriting commissions or discounts. We have agreed in the sales agreement to provide indemnification and contribution to the sales agent against certain civil liabilities, including liabilities under the Securities Act.

We estimate that the total expenses of the offering payable by us, excluding discounts and commissions payable to the sales agent under the sales agreement, will be approximately $100,000, which amount includes up to $50,000 that we have agreed to reimburse Jefferies for the fees and expenses of their counsel. In accordance with FINRA Rule 5110 these reimbursed fees and expenses are deemed sales compensation to Jefferies in connection with this offering.

The offering of shares pursuant to the sales agreement will terminate upon the earlier of (1) the sale of all of the shares subject to the sales agreement and (2) the termination of the sales agreement by the sales agent or us.

The sales agent has from time to time provided, and in the future may provide, certain commercial banking, investment banking and financial advisory services to us and our affiliates, for which it has received, and in the future will receive, customary fees. In the course of its business, Jefferies may actively trade our securities for its own account or for the accounts of customers, and, accordingly, Jefferies may at any time hold long or short positions in such securities.

Table of Contents

This prospectus supplement and the accompanying prospectus in electronic format may be made available on a website maintained by Jefferies and Jefferies may distribute this prospectus supplement and the accompanying prospectus electronically.

Table of Contents

LEGAL MATTERS

The validity of the shares of common stock offered hereby will be passed upon for us by Cooley LLP, San Diego, California. Covington & Burling LLP, New York, New York is counsel to Jefferies in connection with this offering.

Table of Contents

EXPERTS

Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017, as set forth in their report, which is incorporated by reference in this prospectus supplement and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst & Young LLP s report, given on their authority as experts in accounting and auditing.

Table of Contents

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

The SEC allows us to incorporate by reference information from other documents that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus supplement and the accompanying prospectus. Information in this prospectus supplement supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus supplement, while information that we file later with the SEC will automatically update and supersede the information in this prospectus supplement and the accompanying prospectus. We incorporate by reference the documents listed below and any future filings made with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act between the date of this prospectus supplement and the termination of the offering (other than, unless otherwise specifically indicated, current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items):

- our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 13, 2018;
- the information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December 31, 2017 from our Definitive Proxy Statement on Schedule 14A filed with the SEC on April 26, 2018;
- our Quarterly Reports on Form 10-Q filed with the SEC for the quarters ended March 31, 2018 and June 30, 2018, filed with the SEC on May 5, 2018 and August 7, 2018, respectively;
- our Current Reports on Form 8-K filed with the SEC on February 23, 2018, March 13, 2018, April 16, 2018, April 18, 2018, June 15, 2018, July 16, 2018 and October 5, 2018;
- the description of our common stock contained in our registration statement on Form 8-A filed with the SEC on December 10, 2014, under Section 12 of the Exchange Act, including any amendments or reports filed for the purpose of updating such description.

We will provide to each person, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus supplement, including exhibits which are specifically incorporated by reference into such documents. You should direct any requests for documents by writing us at 2130 W. Holcombe Blvd., Ste. 800, Houston, Texas 77030, Attn: Corporate Secretary or telephoning us at (832) 384-1100.

Table of Contents

PROSPECTUS

$150,000,000

Common Stock

Preferred Stock

Debt Securities

Warrants

From time to time, we may offer up to $150,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable antidilution provisions.

This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered.

This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement.

Our common stock is traded on the Nasdaq Global Market under the symbol BLCM. On August 3, 2018, the last reported sales price of our common stock was $5.87 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on the Nasdaq Global Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement.

We will sell these securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled Plan of Distribution in this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such

sale will also be set forth in a prospectus supplement.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading Risk Factors contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The date of this prospectus is August 23, 2018.

Table of Contents

TABLE OF CONTENTS

Table of Contents

ABOUT THIS PROSPECTUS

12,917

67.2700
08:45:06
LSE
636558
12,141
67.2700
08:45:06
LSE
636556
13,197
67.2500
08:45:59
LSE
638286
14,178
67.2400
08:46:05
LSE
638579
6,398
67.2000
08:47:52
LSE
641454
6,064
67.2000
08:48:00
LSE
641627
12,524
67.1800
08:48:19
LSE
642124
13,132
67.1400
08:51:01
LSE
646396
14,712
67.1500
08:52:35
LSE
649254

12,789
67.1400
08:55:51
LSE
655949
14,187
67.2000
08:59:25
LSE
664630
14,632
67.2000
08:59:25
LSE
664628
12,995
67.2300
09:01:55
LSE
668734
10,756
67.2300
09:01:55
LSE
668738
2,731
67.2300
09:01:55
LSE
668736
1,844
67.2200
09:02:48
LSE
669806
12,705
67.2200
09:02:48
LSE
669804
9,553
67.2100
09:03:00
LSE
670036
4,084
67.2100
09:03:00
LSE
670034
4,785

67.1900
09:04:59
LSE
673155
9,190
67.1900
09:04:59
LSE
673153
5,050
67.2100
09:06:29
LSE
675983
9,455
67.2100
09:06:29
LSE
675985
2,844
67.2100
09:07:14
LSE
677019
11,641
67.2100
09:07:14
LSE
677021
12,955
67.1600
09:10:26
LSE
683542
5,640
67.2000
09:14:43
LSE
689637
6,931
67.2000
09:14:43
LSE
689635
13,272
67.2100
09:14:43
LSE
689630
14,024
67.2100

09:14:43
LSE
689628
10,556
67.1800
09:16:04
LSE
691509
3,935
67.1800
09:16:04
LSE
691507
12,903
67.2400
09:21:44
LSE
699382
15,721
67.2400
09:21:44
LSE
699380
4,924
67.2300
09:22:09
LSE
699918
13,703
67.2300
09:22:09
LSE
699916
8,162
67.2300
09:22:09
LSE
699914
8,319
67.2000
09:24:38
LSE
703719
6,032
67.2000
09:24:38
LSE
703717
8,822
67.1900
09:25:05

LSE
704245
3,148
67.1900
09:25:06
LSE
704258
11,732
67.1900
09:26:49
LSE
706509
2,082
67.1900
09:26:49
LSE
706511
13,874
67.2200
09:29:44
LSE
710268
14,056
67.2200
09:29:44
LSE
710266
14,617
67.2100
09:30:20
LSE
711042
12,331
67.2100
09:30:20
LSE
711040
9,237
67.2000
09:31:03
LSE
711958
3,912
67.2000
09:31:03
LSE
711956
14,160
67.1900
09:31:45
LSE

713011
3,754
67.1600
09:32:54
LSE
714512
9,000
67.1600
09:32:54
LSE
714510
9,634
67.1400
09:36:16
LSE
718718
2,363
67.1400
09:36:16
LSE
718716
12,952
67.1400
09:39:00
LSE
722413
1,110
67.1400
09:39:00
LSE
722411
13,018
67.1400
09:39:00
LSE
722409
373
67.1600
09:48:08
LSE
734691
16,901
67.1600
09:48:08
LSE
734687
15,368
67.1600
09:48:08
LSE
734689

13,261
67.1500
09:48:11
LSE
734805
12,416
67.1500
09:48:11
LSE
734807
13,260
67.1800
09:50:26
LSE
738300
13,995
67.1800
09:50:26
LSE
738298
12,196
67.1900
09:52:57
LSE
741002
13,611
67.1900
09:52:57
LSE
741000
13,973
67.1600
10:00:08
LSE
750105
14,228
67.1700
10:00:08
LSE
750098
12,695
67.1700
10:00:08
LSE
750093
12,521
67.1700
10:00:08
LSE
750091
14,695

67.1200
10:04:29
LSE
758978
12,802
67.1100
10:05:52
LSE
760674
7,500
67.1000
10:05:55
LSE
760769
10,557
67.1000
10:05:55
LSE
760767
7,000
67.1000
10:05:55
LSE
760764
14,647
67.1000
10:05:55
LSE
760754
13,947
67.1000
10:05:55
LSE
760748
882
67.1000
10:05:55
LSE
760750
11,695
67.1000
10:05:55
LSE
760752
10,983
67.1000
10:05:55
LSE
760756
14,375
67.1000

10:05:55
LSE
760758
2,459
67.1000
10:05:55
LSE
760760
12,855
67.1000
10:05:55
LSE
760762
14,227
67.1000
10:05:55
LSE
760736
19,281
67.1000
10:05:55
LSE
760728
14,542
67.1000
10:05:55
LSE
760730
14,488
67.1000
10:05:55
LSE
760732
10,529
67.1000
10:05:55
LSE
760734
1,715
67.1000
10:05:55
LSE
760740
14,061
67.1000
10:05:55
LSE
760738
14,683
67.1000
10:05:55

LSE
760744
12,108
67.1000
10:05:55
LSE
760746
2,698
67.1000
10:05:55
LSE
760742
9,441
67.1000
10:06:01
LSE
760866
18,429
67.1000
10:06:01
LSE
760864
2,789
67.1000
10:06:05
LSE
760940
12,012
67.1000
10:06:22
LSE
761343
6,072
67.1000
10:06:22
LSE
761339
12,895
67.1000
10:06:22
LSE
761341
89,701
67.1000
10:06:54
LSE
761997
6,053
67.1600
10:10:41
LSE

766936
8,983
67.1600
10:10:41
LSE
766934
15,612
67.1600
10:10:41
LSE
766932
12,763
67.1700
10:13:44
LSE
771034
12,879
67.1700
10:13:44
LSE
771036
727
67.1700
10:13:44
LSE
771032
11,761
67.1800
10:13:44
LSE
771030
1,028
67.1800
10:13:44
LSE
771028
13,369
67.1800
10:13:44
LSE
771026
12,267
67.1400
10:18:11
LSE
775939
12,950
67.1400
10:18:11
LSE
775937

18,128
67.0900
10:19:30
LSE
777304
67,800
67.0900
10:19:30
LSE
777302
59,271
67.0800
10:19:37
LSE
777445
13,220
67.0800
10:19:37
LSE
777443
13,617
67.0800
10:19:37
LSE
777447
49,730
67.0800
10:19:49
LSE
777751
41,327
67.0700
10:19:51
LSE
777797
13,207
67.0600
10:20:01
LSE
778106
31,503
67.0600
10:20:01
LSE
778104
6,153
67.0600
10:20:01
LSE
778102
6,689

67.0600
10:20:01
LSE
778100
15,422
67.0500
10:20:08
LSE
778285
7,010
67.0500
10:20:08
LSE
778283
21,901
67.0400
10:20:17
LSE
778410
12,726
67.0100
10:20:42
LSE
778950
13,851
67.0100
10:20:42
LSE
778948
18,928
67.0100
10:20:42
LSE
778946
22,839
67.0200
10:20:42
LSE
778944
21,163
67.0300
10:20:42
LSE
778942
16,975
66.9900
10:20:58
LSE
779162
17,886
67.0000

10:20:58
LSE
779159
13,690
66.9900
10:22:25
LSE
780954
6,186
66.9900
10:22:25
LSE
780952
13,066
66.9900
10:22:25
LSE
780950
7,507
66.9900
10:22:25
LSE
780948
14,769
66.9800
10:22:39
LSE
781183
13,880
66.9700
10:22:46
LSE
781266
12,004
67.0700
10:24:35
LSE
783407
14,137
67.0700
10:24:35
LSE
783405
13,108
67.0700
10:24:35
LSE
783403
11,845
67.0500
10:25:04

LSE
783967
13,993
67.0400
10:27:11
LSE
786502
7,902
67.0400
10:27:11
LSE
786500
4,486
67.0400
10:27:11
LSE
786498
12,757
67.0000
10:28:45
LSE
788591
2,675
67.0000
10:31:32
LSE
792032
5,465
67.0000
10:31:32
LSE
792030
11,025
67.0000
10:31:32
LSE
792028
8,616
67.0000
10:31:32
LSE
792026
12,352
66.9800
10:31:52
LSE
792393
12,209
67.0800
10:38:21
LSE

799779
13,143
67.0800
10:38:21
LSE
799777
14,213
67.0800
10:38:21
LSE
799775
5,679
67.1400
10:40:44
LSE
803237
12,010
67.1400
10:40:44
LSE
803239
6,877
67.1400
10:40:44
LSE
803241
3,257
67.1300
10:40:45
LSE
803252
9,021
67.1300
10:40:45
LSE
803250
14,318
67.1400
10:43:31
LSE
806325
11,842
67.1500
10:45:34
LSE
808845
13,436
67.1400
10:45:41
LSE
808944

12,666
67.1400
10:46:24
LSE
809815
18,982
67.1000
10:49:35
LSE
813285
12,331
67.1000
10:49:35
LSE
813259
13,227
67.1000
10:49:35
LSE
813254
12,631
67.1000
10:49:35
LSE
813257
15,938
67.0900
10:50:24
LSE
814309
12,510
67.0800
10:50:26
LSE
814363
8,872
67.1000
10:53:11
LSE
817723
12,790
67.1000
10:53:11
LSE
817721
13,763
67.1000
10:53:11
LSE
817719
4,210

67.1000
10:53:11
LSE
817725
12,239
67.0900
10:57:27
LSE
822599
12,432
67.0900
10:57:27
LSE
822601
13,386
67.0900
10:57:27
LSE
822603
12,361
67.0900
11:03:03
LSE
827600
4,582
67.0900
11:03:03
LSE
827598
13,593
67.0900
11:03:03
LSE
827596
9,767
67.0900
11:03:03
LSE
827594
13,165
67.0900
11:04:59
LSE
829191
13,425
67.0900
11:04:59
LSE
829189
12,018
67.0900

11:04:59
LSE
829187
1,601
67.1200
11:09:05
LSE
832075
11,919
67.1200
11:09:05
LSE
832073
12,543
67.1200
11:09:05
LSE
832077
12,693
67.1200
11:12:31
LSE
835015
12,006
67.1200
11:12:31
LSE
835013
1,658
67.1000
11:12:39
LSE
835169
8,297
67.1000
11:13:53
LSE
836115
2,763
67.1000
11:13:53
LSE
836113
14,381
67.0900
11:14:30
LSE
836650
1,913
67.0800
11:14:38

LSE
836826
2,634
67.0800
11:15:05
LSE
837187
14,645
67.0800
11:15:13
LSE
837366
13,833
67.0800
11:15:13
LSE
837364
8,960
67.0800
11:15:13
LSE
837362
11,933
67.0500
11:18:09
LSE
839400
12,106
67.0500
11:18:09
LSE
839398
12,165
67.0500
11:18:09
LSE
839396
10,800
67.0400
11:19:06
LSE
840053
1,314
67.0400
11:19:10
LSE
840143
5,258
67.0200
11:20:22
LSE

841179
8,255
67.0200
11:20:34
LSE
841323
13,137
67.0200
11:20:34
LSE
841321
14,508
66.9800
11:22:06
LSE
842772
6,109
66.9600
11:23:14
LSE
843516
13,562
66.9600
11:23:14
LSE
843514
5,680
66.9600
11:23:14
LSE
843512
13,250
66.9600
11:25:10
LSE
845052
13,870
66.9500
11:27:09
LSE
846827
13,766
66.9500
11:27:09
LSE
846825
6,788
66.9400
11:29:47
LSE
848542

7,000
66.9400
11:29:47
LSE
848540
11,991
66.9400
11:29:47
LSE
848530
13,762
66.9300
11:29:48
LSE
848576
11,896
66.9300
11:31:08
LSE
849944
14,555
66.9300
11:37:18
LSE
854432
14,469
66.9300
11:37:18
LSE
854430
12,703
66.9300
11:37:18
LSE
854428
13,907
66.9200
11:37:27
LSE
854525
13,303
66.9200
11:37:27
LSE
854527
14,630
66.9100
11:37:41
LSE
854712
14,485

66.9000
11:42:21
LSE
858576
10,213
66.9000
11:42:21
LSE
858574
2,896
66.9000
11:42:21
LSE
858572
13,974
66.9000
11:42:21
LSE
858570
13,345
66.8700
11:43:42
LSE
859527
3,204
66.8700
11:43:42
LSE
859525
9,555
66.8700
11:43:42
LSE
859529
13,505
66.8500
11:46:24
LSE
861415
4,000
66.8400
11:48:11
LSE
863004
13,614
66.8400
11:48:46
LSE
863460
5,125
66.8400

11:48:46
LSE
863458
3,246
66.8400
11:48:46
LSE
863456
14,132
66.8200
11:50:51
LSE
865086
12,056
66.8000
11:51:11
LSE
865315
14,144
66.8200
11:55:28
LSE
868694
13,896
66.8200
11:55:28
LSE
868692
13,934
66.8200
11:55:28
LSE
868690
5,055
66.8100
11:55:32
LSE
868750
12,077
66.8100
11:55:32
LSE
868748
8,474
66.8100
11:55:32
LSE
868752
6,246
66.8300
11:59:44

LSE
872447
11,178
66.8300
11:59:44
LSE
872445
12,313
66.8300
11:59:44
LSE
872443
6,861
66.8300
11:59:44
LSE
872441
1,631
66.8300
11:59:44
LSE
872439
12,505
66.8500
12:02:29
LSE
875278
13,207
66.8500
12:02:29
LSE
875280
13,180
66.8500
12:02:29
LSE
875276
11,852
66.8400
12:02:52
LSE
875648
1,075
66.8900
12:06:45
LSE
878778
2,842
66.8900
12:07:11
LSE

879059
4,254
66.8900
12:08:30
LSE
880005
14,594
66.8900
12:08:30
LSE
880003
13,701
66.8900
12:08:30
LSE
880001
785
66.8900
12:08:30
LSE
879997
5,108
66.8900
12:08:30
LSE
879995
13,514
66.8900
12:09:42
LSE
880802
12,344
66.8900
12:09:42
LSE
880800
12,954
66.8900
12:09:42
LSE
880798
13,985
66.9000
12:10:22
LSE
881295
13,354
66.9000
12:10:22
LSE
881293

14,598
66.8800
12:11:44
LSE
882193
2,835
66.8600
12:12:03
LSE
882509
10,690
66.8600
12:12:03
LSE
882507
12,521
66.8600
12:12:03
LSE
882505
14,606
66.8000
12:15:05
LSE
884778
12,236
66.8000
12:15:05
LSE
884776
14,490
66.8000
12:15:05
LSE
884774
13,050
66.8000
12:15:05
LSE
884772
24,531
66.8000
12:15:05
LSE
884768
13,275
66.8000
12:15:05
LSE
884770
2,222

66.8000
12:19:27
LSE
887960
6,809
66.8100
12:19:48
LSE
888145
14,404
66.8400
12:20:58
LSE
889049
14,497
66.8400
12:20:58
LSE
889051
14,128
66.8400
12:20:58
LSE
889053
3,543
66.8500
12:22:57
LSE
890598
750
66.8500
12:23:07
LSE
890736
2,393
66.8500
12:23:31
LSE
890955
1,030
66.8500
12:24:06
LSE
891499
5,247
66.8500
12:24:06
LSE
891497
2,676
66.8600

12:25:00
LSE
892079
7,140
66.8600
12:25:15
LSE
892393
7,605
66.8600
12:25:34
LSE
892592
12,169
66.8600
12:25:34
LSE
892590
7,465
66.8600
12:25:34
LSE
892594
4,404
66.8600
12:25:34
LSE
892584
2,195
66.8600
12:25:34
LSE
892586
5,131
66.8700
12:26:11
LSE
893195
7,631
66.8700
12:26:11
LSE
893193
12,272
66.8700
12:26:11
LSE
893191
12,186
66.8400
12:27:24

LSE
894061
13,340
66.8300
12:28:05
LSE
894574
12,978
66.8300
12:28:05
LSE
894572
7,025
66.8000
12:30:16
LSE
896105
13,914
66.8000
12:30:16
LSE
896097
2,000
66.8000
12:30:16
LSE
896099
10,527
66.8000
12:30:16
LSE
896101
11,085
66.8000
12:30:16
LSE
896103
5,026
66.8100
12:33:19
LSE
897926
2,391
66.8100
12:34:43
LSE
898902
2,779
66.8100
12:35:18
LSE

899380
10,692
66.8200
12:35:50
LSE
899905
14,322
66.8200
12:35:50
LSE
899907
11,999
66.8200
12:35:50
LSE
899909
2,682
66.8200
12:35:50
LSE
899901
1,547
66.8200
12:36:17
LSE
900344
11,985
66.8200
12:36:17
LSE
900342
14,477
66.8200
12:36:17
LSE
900340
9,423
66.8000
12:37:07
LSE
900898
14,129
66.8000
12:38:25
LSE
901807
11,860
66.8000
12:38:25
LSE
901805

15,843
66.8000
12:38:25
LSE
901803
22,052
66.8000
12:38:25
LSE
901801
12,924
66.8000
12:38:25
LSE
901799
42,597
66.7900
12:39:03
LSE
902159
26,534
66.7800
12:39:14
LSE
902363
14,658
66.7800
12:39:14
LSE
902361
8,499
66.7700
12:39:40
LSE
902661
16,120
66.7700
12:39:40
LSE
902659
10,136
66.7600
12:41:20
LSE
904311
23,070
66.8000
12:46:11
LSE
908013
15,302

66.8000
12:46:11
LSE
908011
14,177
66.8000
12:46:11
LSE
908015
12,436
66.8000
12:46:11
LSE
908009
14,663
66.8400
12:48:44
LSE
909748
14,366
66.8400
12:48:44
LSE
909746
12,225
66.8400
12:48:44
LSE
909744
14,424
66.8400
12:49:01
LSE
909955
13,850
66.8400
12:49:01
LSE
909953
12,025
66.8400
12:50:27
LSE
911032
1,867
66.8600
12:56:03
LSE
915782
7,536
66.8600

12:56:42
LSE
916130
7,200
66.8600
12:57:30
LSE
916721
7,000
66.8600
12:57:30
LSE
916719
14,018
66.8600
12:57:30
LSE
916717
520
66.8600
12:57:30
LSE
916715
13,560
66.8600
12:57:30
LSE
916713
3,527
66.8600
12:57:30
LSE
916711
12,582
66.8300
12:58:30
LSE
917469
12,360
66.8300
12:58:30
LSE
917467
11,522
66.8000
13:00:07
LSE
918792
9,270
66.8000
13:00:20

LSE
919071
2,913
66.8000
13:00:24
LSE
919132
579
66.8000
13:00:45
LSE
919413
7,440
66.8000
13:00:45
LSE
919411
15,674
66.8000
13:01:32
LSE
920055
12,092
66.8000
13:01:32
LSE
920049
5,660
66.8000
13:01:32
LSE
920051
857
66.8000
13:01:32
LSE
920053
11,888
66.8000
13:01:32
LSE
920057
13,737
66.8000
13:01:32
LSE
920059
7,581
66.8000
13:01:32
LSE

920061
5,024
66.8000
13:01:32
LSE
920063
8,640
66.8000
13:02:39
LSE
920988
627
66.8000
13:02:39
LSE
920986
636
66.8000
13:02:43
LSE
921031
5,216
66.8000
13:02:44
LSE
921033
4,617
66.8000
13:02:59
LSE
921193
2,759
66.8000
13:03:18
LSE
921583
7,403
66.8000
13:03:23
LSE
921670
4,905
66.8000
13:03:32
LSE
921764
12,795
66.8000
13:03:32
LSE
921762

9,744
66.8000
13:03:32
LSE
921760
4,075
66.8000
13:03:32
LSE
921758
21,059
66.7900
13:03:43
LSE
921883
12,169
66.7900
13:03:43
LSE
921881
737
66.7900
13:03:43
LSE
921879
23,032
66.7900
13:04:05
LSE
922207
14,440
66.7900
13:04:05
LSE
922205
13,559
66.7800
13:04:21
LSE
922450
22,238
66.7800
13:04:21
LSE
922448
5,614
66.7700
13:04:38
LSE
922707
12,105

66.7700
13:05:03
LSE
923059
3,011
66.7600
13:05:19
LSE
923312
15,185
66.7700
13:05:19
LSE
923300
3,510
66.7700
13:05:19
LSE
923298
12,982
66.7600
13:05:30
LSE
923462
6,155
66.7600
13:05:32
LSE
923482
3,505
66.7600
13:05:49
LSE
923811
8,618
66.7600
13:05:49
LSE
923809
2,812
66.7600
13:05:49
LSE
923807
4,440
66.7600
13:05:49
LSE
923805
919
66.7600

13:05:49
LSE
923803
14,101
66.7700
13:07:35
LSE
925384
7,997
66.7700
13:07:35
LSE
925386
6,003
66.7700
13:07:35
LSE
925388
4,796
66.7700
13:07:35
LSE
925390
8,431
66.7700
13:07:35
LSE
925392
13,981
66.7700
13:07:35
LSE
925394
12,931
66.7900
13:09:42
LSE
927207
14,462
66.7900
13:09:42
LSE
927205
12,524
66.8200
13:12:59
LSE
930000
12,793
66.8200
13:12:59

LSE
929998
14,533
66.7900
13:13:26
LSE
930374
14,442
66.8000
13:13:26
LSE
930369
13,107
66.8100
13:13:26
LSE
930367
14,620
66.8100
13:13:26
LSE
930365
13,939
66.8100
13:13:26
LSE
930363
12,271
66.7800
13:13:57
LSE
930825
13,654
66.7900
13:15:01
LSE
931917
14,474
66.7800
13:15:28
LSE
932272
11,862
66.7800
13:15:28
LSE
932270
13,586
66.7700
13:17:11
LSE

933610
4,401
66.7700
13:17:11
LSE
933608
9,544
66.7700
13:17:11
LSE
933606
12,043
66.7700
13:19:00
LSE
935515
12,202
66.7600
13:19:49
LSE
936171
13,461
66.7600
13:19:49
LSE
936167
14,462
66.7600
13:19:49
LSE
936165
2,715
66.7500
13:20:00
LSE
936423
11,329
66.7500
13:20:00
LSE
936421
13,138
66.7400
13:20:46
LSE
937057
11,689
66.7400
13:22:22
LSE
938673

12,334
66.7600
13:23:20
LSE
939443
1,495
66.7600
13:23:20
LSE
939445
10,799
66.7600
13:23:20
LSE
939447
1,803
66.7600
13:23:20
LSE
939449
12,451
66.7900
13:25:29
LSE
941317
12,735
66.7900
13:25:29
LSE
941315
12,060
66.7900
13:25:29
LSE
941313
12,041
66.7900
13:25:29
LSE
941311
1,603
66.7900
13:28:05
LSE
943847
5,968
66.7900
13:28:38
LSE
944241
4,764

66.7900
13:29:15
LSE
944709
4,942
66.7900
13:29:15
LSE
944717
4,583
66.7900
13:29:15
LSE
944705
1,114
66.7900
13:29:15
LSE
944707
7,535
66.7900
13:29:15
LSE
944703
13,009
66.7900
13:29:15
LSE
944711
9,493
66.7900
13:29:15
LSE
944713
7,520
66.7900
13:29:15
LSE
944715
4,459
66.7900
13:29:15
LSE
944701
7,531
66.7800
13:30:27
LSE
946274
4,301
66.7800

13:31:33
LSE
947567
12,201
66.7800
13:31:33
LSE
947565
7,927
66.7800
13:31:33
LSE
947563
9,306
66.7800
13:31:33
LSE
947561
4,312
66.7800
13:31:33
LSE
947559
6,498
66.7800
13:31:33
LSE
947557
10,215
66.7800
13:31:33
LSE
947555
4,409
66.7800
13:31:33
LSE
947553
13,587
66.7700
13:31:39
LSE
947682
12,918
66.7600
13:31:51
LSE
947838
13,618
66.7600
13:32:56

LSE
948841
12,783
66.7600
13:32:56
LSE
948843
12,325
66.7700
13:33:26
LSE
949368
12,991
66.7900
13:36:00
LSE
951816
13,681
66.7900
13:36:00
LSE
951814
1,667
66.7900
13:37:50
LSE
953409
1,583
66.7900
13:38:00
LSE
953557
12,913
66.7900
13:38:00
LSE
953555
8,283
66.7900
13:39:05
LSE
954513
4,833
66.7900
13:39:05
LSE
954511
13,582
66.7900
13:39:05
LSE

954515
14,547
66.7900
13:39:05
LSE
954517
12,588
66.7900
13:40:24
LSE
955741
13,582
66.7900
13:40:24
LSE
955739
14,522
66.7900
13:40:24
LSE
955737
3,554
66.7700
13:40:40
LSE
955987
10,922
66.7700
13:40:40
LSE
955985
1,013
66.7900
13:45:06
LSE
960367
11,323
66.7900
13:45:06
LSE
960365
3,015
66.7900
13:45:06
LSE
960363
14,460
66.7900
13:45:06
LSE
960361

11,029
66.7900
13:45:06
LSE
960359
13,095
66.7900
13:45:06
LSE
960357
12,973
66.7800
13:45:30
LSE
960911
12,012
66.7800
13:45:30
LSE
960909
12,673
66.7800
13:45:30
LSE
960907
3,715
66.7900
13:47:56
LSE
963416
9,757
66.7900
13:47:56
LSE
963414
11,611
66.7900
13:47:56
LSE
963408
621
66.7900
13:47:56
LSE
963412
12,677
66.7900
13:47:56
LSE
963410
13,912

66.7900
13:49:05
LSE
964822
13,050
66.7900
13:49:05
LSE
964820
13,423
66.7900
13:49:05
LSE
964818
14,050
66.7600
13:50:03
LSE
966269
12,809
66.7600
13:53:14
LSE
969617
13,777
66.7600
13:53:14
LSE
969615
12,895
66.7600
13:53:14
LSE
969619
12,597
66.7600
13:53:14
LSE
969621
12,209
66.7700
13:54:39
LSE
971042
6,895
66.7700
13:54:39
LSE
971040
3,703
66.7700

13:54:39
LSE
971038
7,097
66.7700
13:54:39
LSE
971036
9,670
66.7700
13:54:39
LSE
971034
14,476
66.7800
13:55:16
LSE
971936
13,567
66.7800
13:55:16
LSE
971934
13,154
66.7500
13:58:06
LSE
974788
4,959
66.7600
13:58:06
LSE
974782
8,600
66.7600
13:58:06
LSE
974780
12,883
66.7600
13:58:06
LSE
974772
12,631
66.7600
13:58:06
LSE
974774
13,179
66.7600
13:58:06

LSE
974778
12,051
66.7600
13:58:06
LSE
974776
14,310
66.7300
13:58:35
LSE
975319
14,185
66.7200
13:58:56
LSE
975681
13,682
66.7500
14:02:03
LSE
979381
2,931
66.7500
14:02:03
LSE
979379
12,563
66.7500
14:02:03
LSE
979377
9,036
66.7500
14:02:03
LSE
979375
597
66.7500
14:02:03
LSE
979373
14,017
66.7500
14:02:03
LSE
979371
6,587
66.7500
14:03:07
LSE

980374
7,586
66.7500
14:03:07
LSE
980370
5,282
66.7500
14:03:07
LSE
980372
5,113
66.7700
14:06:27
LSE
984891
9,455
66.7700
14:06:27
LSE
984889
8,760
66.7700
14:06:27
LSE
984885
7,209
66.7700
14:06:27
LSE
984893
20,009
66.7700
14:06:27
LSE
984897
14,860
66.7700
14:06:27
LSE
984895
1,344
66.7700
14:06:27
LSE
984887
14,276
66.7600
14:06:42
LSE
985335

15,438
66.7600
14:06:42
LSE
985333
14,047
66.7600
14:06:42
LSE
985331
13,624
66.7600
14:06:42
LSE
985329
12,645
66.7500
14:06:51
LSE
985532
13,713
66.7400
14:06:55
LSE
985589
13,961
66.7400
14:06:55
LSE
985587
6,989
66.7300
14:07:02
LSE
985708
6,067
66.7300
14:07:02
LSE
985706
12,944
66.7400
14:09:38
LSE
988445
13,848
66.7400
14:09:38
LSE
988443
11,793

66.7400
14:09:38
LSE
988441
9,755
66.7400
14:09:38
LSE
988439
2,757
66.7400
14:09:38
LSE
988437
13,380
66.7600
14:11:20
LSE
990095
13,713
66.8400
14:14:27
LSE
993117
14,839
66.8400
14:14:27
LSE
993115
14,484
66.8400
14:14:27
LSE
993113
8,631
66.8900
14:20:18
LSE
999546
9,479
66.8900
14:20:18
LSE
999544
1,321
66.8900
14:20:18
LSE
999542
10,799
66.8900

14:20:18
LSE
999540
17,944
66.8900
14:20:18
LSE
999538
5,493
66.8900
14:20:18
LSE
999536
5,985
66.8700
14:20:56
LSE
1000417
7,000
66.8700
14:20:56
LSE
1000415
13,893
66.8800
14:20:56
LSE
1000413
14,408
66.8800
14:20:56
LSE
1000411
14,692
66.8800
14:20:56
LSE
1000409
12,841
66.9200
14:23:08
LSE
1003037
12,200
66.9200
14:23:08
LSE
1003035
13,415
66.9200
14:23:08

LSE
1003033
12,672
66.9000
14:23:09
LSE
1003058
12,464
66.9000
14:23:09
LSE
1003056
13,829
66.9000
14:23:09
LSE
1003054
13,331
66.9100
14:23:09
LSE
1003050
12,992
66.9100
14:23:09
LSE
1003052
7,362
66.8800
14:26:16
LSE
1006732
9,165
66.8800
14:26:37
LSE
1007152
10,356
66.8800
14:26:37
LSE
1007150
3,160
66.8800
14:26:37
LSE
1007156
1,634
66.8800
14:26:37
LSE

1007154
5,051
66.8800
14:26:37
LSE
1007148
13,311
66.8400
14:27:52
LSE
1008777
13,070
66.8400
14:27:52
LSE
1008775
12,156
66.8400
14:27:52
LSE
1008773
2,335
66.8600
14:29:48
LSE
1011650
11,011
66.8600
14:29:48
LSE
1011648
12,555
66.8600
14:29:48
LSE
1011646
11,822
66.8600
14:29:48
LSE
1011644
12,905
66.8700
14:31:36
LSE
1020613
10,816
66.8700
14:31:36
LSE
1020615

11,809
66.8700
14:31:36
LSE
1020617
1,726
66.8700
14:31:36
LSE
1020619
12,988
66.8600
14:32:20
LSE
1022479
12,056
66.8600
14:32:20
LSE
1022477
14,027
66.8600
14:32:20
LSE
1022475
13,659
66.8700
14:33:16
LSE
1024740
11,864
66.8700
14:33:16
LSE
1024738
13,173
66.8700
14:33:16
LSE
1024736
3,667
66.8800
14:33:16
LSE
1024723
11,871
66.8800
14:33:16
LSE
1024721
10,799

66.8800
14:33:16
LSE
1024719
215
66.8800
14:33:16
LSE
1024717
12,685
66.8800
14:33:16
LSE
1024715
4,105
66.8000
14:35:04
LSE
1028792
7,714
66.8000
14:35:04
LSE
1028794
13,096
66.8000
14:35:04
LSE
1028796
12,565
66.8000
14:35:04
LSE
1028798
13,850
66.8000
14:35:04
LSE
1028800
14,520
66.8000
14:35:04
LSE
1028802
12,150
66.8000
14:35:04
LSE
1028790
11,913
66.8000

14:35:04
LSE
1028788
13,552
66.7900
14:35:05
LSE
1028881
5,063
66.7900
14:35:05
LSE
1028879
18,844
66.7900
14:35:05
LSE
1028877
2,785
66.7900
14:35:05
LSE
1028875
27,094
66.7800
14:35:23
LSE
1029755
24,517
66.7700
14:35:44
LSE
1030522
14,402
66.7700
14:35:44
LSE
1030524
14,256
66.7500
14:35:53
LSE
1030792
2,432
66.7500
14:35:53
LSE
1030790
9,511
66.7500
14:35:53

LSE
1030788
19,796
66.7400
14:35:56
LSE
1030908
147
66.7400
14:36:02
LSE
1031067
4,385
66.7400
14:36:02
LSE
1031065
1,638
66.7500
14:36:58
LSE
1033138
12,000
66.7500
14:36:58
LSE
1033136
14,189
66.7500
14:36:58
LSE
1033132
11,982
66.7500
14:36:58
LSE
1033134
14,250
66.7500
14:36:58
LSE
1033130
4,043
66.7400
14:37:07
LSE
1033661
10,799
66.7400
14:37:07
LSE

1033659
5,590
66.7400
14:37:07
LSE
1033657
8,953
66.7300
14:37:12
LSE
1033951
22,623
66.7500
14:38:02
LSE
1035710
10,867
66.7500
14:38:02
LSE
1035708
1,755
66.7500
14:38:02
LSE
1035706
19,068
66.7400
14:38:06
LSE
1035966
12,394
66.7400
14:38:06
LSE
1035964
14,521
66.7300
14:39:13
LSE
1038277
20,468
66.7300
14:39:13
LSE
1038275
7,049
66.7300
14:39:40
LSE
1039378

10,872
66.7300
14:39:46
LSE
1039594
7,000
66.7300
14:39:46
LSE
1039592
19,559
66.7300
14:39:46
LSE
1039572
5,337
66.7300
14:39:46
LSE
1039570
12,891
66.7700
14:40:38
LSE
1041239
12,728
66.7700
14:40:38
LSE
1041237
16,838
66.7700
14:40:38
LSE
1041235
14,301
66.7700
14:40:38
LSE
1041233
15,324
66.7500
14:40:55
LSE
1041745
13,580
66.7400
14:40:59
LSE
1041825
12,681

66.7400
14:40:59
LSE
1041823
14,058
66.7900
14:43:22
LSE
1046329
11,981
66.7900
14:43:22
LSE
1046331
14,033
66.7900
14:43:22
LSE
1046333
11,900
66.7900
14:43:22
LSE
1046327
15,437
66.7800
14:43:41
LSE
1046930
12,441
66.7800
14:43:41
LSE
1046928
12,999
66.7900
14:44:36
LSE
1049110
13,250
66.7900
14:44:36
LSE
1049108
731
66.7900
14:44:36
LSE
1049106
11,502
66.7900

14:44:36
LSE
1049102
14,577
66.7900
14:45:34
LSE
1051296
12,139
66.7900
14:45:34
LSE
1051294
12,328
66.7900
14:45:34
LSE
1051292
439
66.7900
14:45:34
LSE
1051287
10,983
66.7900
14:46:01
LSE
1052051
3,336
66.7900
14:46:01
LSE
1052049
6,672
66.8000
14:48:00
LSE
1055709
13,557
66.8000
14:48:00
LSE
1055705
14,214
66.8000
14:48:00
LSE
1055707
6,282
66.8000
14:48:00

LSE
1055713
713
66.8000
14:48:00
LSE
1055711
14,269
66.8000
14:48:00
LSE
1055715
13,755
66.7900
14:48:08
LSE
1055910
12,558
66.7900
14:48:08
LSE
1055908
5,786
66.7700
14:48:50
LSE
1057302
204
66.7700
14:48:50
LSE
1057271
6,174
66.7700
14:48:50
LSE
1057257
6,814
66.7700
14:48:50
LSE
1057259
1,894
66.7700
14:48:50
LSE
1057255
10,799
66.7700
14:48:50
LSE

1057253
1,167
66.7700
14:48:50
LSE
1057251
900
66.7700
14:48:55
LSE
1057523
2,658
66.8600
14:51:19
LSE
1062068
12,010
66.8600
14:51:19
LSE
1062066
10,893
66.8600
14:51:19
LSE
1062064
13,780
66.8600
14:51:19
LSE
1062062
12,604
66.8500
14:51:30
LSE
1062462
12,430
66.8500
14:51:30
LSE
1062460
441
66.8200
14:52:27
LSE
1064847
1,932
66.8200
14:52:27
LSE
1064849

10,284
66.8200
14:52:27
LSE
1064851
13,879
66.8200
14:52:55
LSE
1065722
12,986
66.8200
14:52:55
LSE
1065720
400
66.8000
14:54:17
LSE
1069199
400
66.8000
14:54:34
LSE
1069870
2,395
66.8000
14:54:40
LSE
1070113
12,893
66.8000
14:54:55
LSE
1070616
11,819
66.8000
14:54:55
LSE
1070618
14,211
66.8000
14:54:55
LSE
1070620
13,637
66.8000
14:54:55
LSE
1070622
14,106

66.8000
14:54:55
LSE
1070624
15,224
66.7900
14:55:50
LSE
1072455
400
66.7900
14:55:59
LSE
1072773
858
66.7900
14:56:10
LSE
1073172
3,659
66.8100
14:57:00
LSE
1074585
400
66.8100
14:57:13
LSE
1074919
400
66.8100
14:57:39
LSE
1075801
400
66.8100
14:57:46
LSE
1075971
400
66.8100
14:57:53
LSE
1076130
400
66.8100
14:57:57
LSE
1076228
800
66.8100

14:57:57
LSE
1076225
2,782
66.8100
14:57:59
LSE
1076268
400
66.8100
14:58:02
LSE
1076358
400
66.8100
14:58:07
LSE
1076536
400
66.8100
14:58:08
LSE
1076580
400
66.8100
14:58:12
LSE
1076706
14,503
66.8200
14:58:28
LSE
1077267
1,065
66.8200
14:58:28
LSE
1077265
12,629
66.8200
14:58:28
LSE
1077271
13,130
66.8200
14:58:28
LSE
1077269
2,110
66.8000
14:58:54

LSE
1078073
12,772
66.8100
14:58:54
LSE
1078071
12,976
66.8100
14:58:54
LSE
1078069
14,086
66.8100
14:58:54
LSE
1078067
11,633
66.8000
14:58:55
LSE
1078092
917
66.8000
14:58:55
LSE
1078090
7,956
66.8000
14:59:01
LSE
1078301
1,636
66.8000
14:59:01
LSE
1078295
4,864
66.8000
14:59:01
LSE
1078293
7,123
66.8000
14:59:01
LSE
1078297
4,326
66.8000
14:59:01
LSE

1078299
12,550
66.7700
14:59:05
LSE
1078501
15,603
66.7900
14:59:05
LSE
1078432
14,469
66.7700
14:59:08
LSE
1078548
160
66.7700
14:59:08
LSE
1078546
806
66.7700
14:59:08
LSE
1078544
12,124
66.8000
15:01:00
LSE
1082792
13,542
66.8000
15:01:00
LSE
1082794
12,672
66.8000
15:01:00
LSE
1082796
14,398
66.8000
15:01:00
LSE
1082798
3,594
66.7900
15:01:28
LSE
1083923

968
66.7900
15:01:32
LSE
1084130
12,039
66.7900
15:01:32
LSE
1084132
753
66.7900
15:01:32
LSE
1084128
7,829
66.7900
15:01:32
LSE
1084126
13,017
66.7900
15:01:32
LSE
1084124
4,015
66.7900
15:01:32
LSE
1084122
5,938
66.7900
15:01:32
LSE
1084120
3,234
66.7900
15:01:32
LSE
1084118
10,481
66.7800
15:01:38
LSE
1084391
1,938
66.7800
15:01:38
LSE
1084389
12,965

66.7400
15:02:13
LSE
1085797
1,454
66.7100
15:02:36
LSE
1086556
2,195
66.7100
15:02:38
LSE
1086613
10,977
66.7100
15:02:42
LSE
1086739
12,054
66.7000
15:02:58
LSE
1087256
272
66.7000
15:02:58
LSE
1087258
12,849
66.7000
15:02:58
LSE
1087260
14,076
66.7200
15:04:09
LSE
1089908
8,751
66.7100
15:04:10
LSE
1089939
9,857
66.7100
15:04:11
LSE
1089966
5,891
66.7100

15:04:11
LSE
1089964
13,035
66.7100
15:04:17
LSE
1090167
1,958
66.7100
15:04:17
LSE
1090165
3,227
66.7000
15:04:25
LSE
1090507
10,726
66.7000
15:04:25
LSE
1090509
7,541
66.6700
15:05:07
LSE
1091970
700
66.6700
15:05:07
LSE
1091966
800
66.6700
15:05:11
LSE
1092192
1,200
66.6700
15:05:13
LSE
1092311
400
66.6700
15:05:14
LSE
1092343
400
66.6700
15:05:14

LSE
1092341
400
66.6700
15:05:18
LSE
1092461
331
66.6700
15:05:20
LSE
1092566
400
66.6700
15:05:20
LSE
1092560
13,861
66.7000
15:06:16
LSE
1094931
14,629
66.7000
15:06:16
LSE
1094929
12,526
66.7000
15:06:16
LSE
1094927
12,676
66.7000
15:06:16
LSE
1094925
14,278
66.7100
15:07:19
LSE
1097453
8,277
66.7200
15:08:30
LSE
1099631
12,358
66.7200
15:08:30
LSE

1099633
12,126
66.7200
15:08:30
LSE
1099635
5,307
66.7200
15:08:30
LSE
1099629
14,193
66.7200
15:08:30
LSE
1099627
13,469
66.7400
15:10:22
LSE
1103295
13,636
66.7400
15:10:22
LSE
1103280
12,185
66.7400
15:10:22
LSE
1103278
12,253
66.7400
15:10:22
LSE
1103276
12,453
66.7400
15:10:22
LSE
1103274
8,568
66.7300
15:11:26
LSE
1105299
100
66.7300
15:11:28
LSE
1105390

14,306
66.7300
15:11:29
LSE
1105452
12,239
66.7300
15:11:29
LSE
1105446
14,042
66.7300
15:11:29
LSE
1105448
3,402
66.7300
15:11:29
LSE
1105450
5,073
66.7800
15:15:05
LSE
1114206
16,006
66.7800
15:15:05
LSE
1114204
16,021
66.7800
15:15:05
LSE
1114202
16,001
66.7800
15:15:19
LSE
1114859
7,187
66.7800
15:15:19
LSE
1114861
13,242
66.7800
15:15:19
LSE
1114863
4,757

66.7800
15:15:19
LSE
1114865
537
66.7800
15:15:19
LSE
1114867
7,540
66.7800
15:15:19
LSE
1114857
5,466
66.7800
15:15:19
LSE
1114855
6,819
66.7700
15:15:47
LSE
1115933
7,395
66.7700
15:15:47
LSE
1115931
11,884
66.7700
15:15:47
LSE
1115929
5,472
66.7600
15:16:07
LSE
1116434
400
66.7600
15:16:24
LSE
1116920
973
66.7600
15:16:44
LSE
1117461
5,491
66.7600

15:16:46
LSE
1117512
5,692
66.7600
15:16:46
LSE
1117514
8,462
66.7600
15:16:57
LSE
1117897
5,798
66.7600
15:16:57
LSE
1117895
400
66.7600
15:16:57
LSE
1117889
4,311
66.7600
15:17:19
LSE
1118478
3,887
66.7600
15:17:19
LSE
1118476
13,823
66.7700
15:17:43
LSE
1119286
7,604
66.7600
15:17:46
LSE
1119353
2,396
66.7600
15:17:46
LSE
1119351
400
66.7600
15:17:56

LSE
1119678
8,082
66.7700
15:18:09
LSE
1120281
14,510
66.7700
15:18:09
LSE
1120279
3,764
66.7700
15:18:09
LSE
1120277
13,777
66.7800
15:18:34
LSE
1121207
12,741
66.7700
15:19:09
LSE
1122601
14,052
66.7700
15:19:09
LSE
1122599
12,521
66.7600
15:19:17
LSE
1122823
489
66.7500
15:19:48
LSE
1123744
14,127
66.7500
15:20:00
LSE
1124082
14,306
66.7500
15:20:00
LSE

1124080
6,571
66.7500
15:20:00
LSE
1124078
2,000
66.7500
15:20:00
LSE
1124076
4,723
66.7500
15:20:00
LSE
1124074
4,118
66.8100
15:22:40
LSE
1128851
9,069
66.8100
15:22:40
LSE
1128847
816
66.8100
15:22:40
LSE
1128849
12,669
66.8100
15:22:40
LSE
1128855
4,924
66.8100
15:22:40
LSE
1128853
9,060
66.8100
15:22:40
LSE
1128857
11,944
66.8100
15:23:04
LSE
1129493

1,299
66.8100
15:23:21
LSE
1129998
915
66.8000
15:24:27
LSE
1132140
8,542
66.8000
15:24:27
LSE
1132136
3,562
66.8000
15:24:29
LSE
1132198
12,114
66.8000
15:24:45
LSE
1133287
13,071
66.8500
15:25:53
LSE
1136583
12,454
66.8500
15:25:53
LSE
1136585
8,906
66.8500
15:25:53
LSE
1136587
5,534
66.8500
15:25:53
LSE
1136589
8,900
66.8500
15:26:20
LSE
1137527
1,006

66.8500
15:26:20
LSE
1137485
4,508
66.8500
15:26:20
LSE
1137483
1,232
66.8500
15:26:20
LSE
1137481
414
66.8500
15:26:20
LSE
1137479
10,442
66.8500
15:26:20
LSE
1137477
7,445
66.8500
15:26:20
LSE
1137475
10,456
66.8600
15:28:08
LSE
1141582
13,625
66.8600
15:28:08
LSE
1141580
11,950
66.8600
15:28:08
LSE
1141578
2,895
66.8600
15:28:08
LSE
1141576
12,805
66.8500

15:28:36
LSE
1142552
13,907
66.8400
15:28:41
LSE
1142755
12,243
66.8300
15:29:08
LSE
1143584
355
66.8800
15:30:15
LSE
1146189
13,891
66.8800
15:30:15
LSE
1146187
14,256
66.9500
15:32:13
LSE
1150054
12,168
66.9500
15:32:13
LSE
1150052
2,448
66.9500
15:32:13
LSE
1150056
14,406
66.9500
15:32:13
LSE
1150050
12,054
66.9400
15:33:07
LSE
1151936
12,441
66.9400
15:33:07

LSE
1151934
5,074
66.9400
15:33:07
LSE
1151932
8,857
66.9400
15:33:07
LSE
1151930
18,651
66.7500
15:59:41
LSE
1210602
13,661
66.7400
15:59:59
LSE
1212201
12,891
66.7400
16:01:02
LSE
1217063
12,975
66.7400
16:01:02
LSE
1217061
11,244
66.7200
16:01:11
LSE
1217336
11,524
66.7200
16:01:11
LSE
1217334
21,711
66.7300
16:01:11
LSE
1217323
1,766
66.7300
16:01:11
LSE

1217325
2,835
66.7500
16:01:58
LSE
1218865
1,101
66.7500
16:01:58
LSE
1218863
62,600
66.7500
16:01:58
LSE
1218867
9,458
66.7500
16:01:58
LSE
1218869
3,011
66.7500
16:01:58
LSE
1218861
3,245
66.7500
16:01:58
LSE
1218859
3,107
66.7500
16:01:58
LSE
1218857
88,289
66.7500
16:01:58
LSE
1218855
14,167
66.7500
16:01:58
LSE
1218853
10,692
66.7400
16:02:31
LSE
1220148

3,163
66.7400
16:02:31
LSE
1220146
13,142
66.7300
16:03:34
LSE
1222372
5,970
66.7100
16:03:43
LSE
1222872
7,219
66.7100
16:03:43
LSE
1222870
15,255
66.7200
16:03:43
LSE
1222865
400
66.6900
16:04:08
LSE
1223867
100
66.6900
16:04:09
LSE
1223891
1,200
66.6900
16:04:09
LSE
1223889
400
66.6900
16:04:10
LSE
1223913
400
66.6900
16:04:10
LSE
1223911
400

66.6900
16:04:11
LSE
1223930
100
66.6900
16:04:12
LSE
1223936
400
66.6900
16:04:12
LSE
1223934
400
66.6900
16:04:13
LSE
1223973
400
66.6900
16:04:13
LSE
1223959
400
66.6900
16:04:13
LSE
1223956
400
66.6900
16:04:15
LSE
1224006
400
66.6900
16:04:17
LSE
1224033
400
66.6900
16:04:18
LSE
1224081
400
66.6900
16:04:18
LSE
1224074
400
66.6900

16:04:20
LSE
1224139
1,600
66.6900
16:04:21
LSE
1224177
400
66.6900
16:04:23
LSE
1224365
400
66.6900
16:04:23
LSE
1224363
400
66.6900
16:04:28
LSE
1224463
6,400
66.7200
16:05:17
LSE
1226502
400
66.7200
16:05:18
LSE
1226551
400
66.7200
16:05:19
LSE
1226627
2,000
66.7200
16:05:19
LSE
1226593
400
66.7200
16:05:19
LSE
1226591
3,227
66.7500
16:05:53

LSE
1227799
10,197
66.7500
16:05:53
LSE
1227797
12,641
66.7500
16:05:53
LSE
1227793
38,471
66.7500
16:05:53
LSE
1227795
6,150
66.7500
16:05:53
LSE
1227791
16,250
66.7400
16:06:04
LSE
1228776
12,032
66.7300
16:06:06
LSE
1228938
13,745
66.7300
16:06:06
LSE
1228936
24,389
66.7300
16:07:15
LSE
1231705
400
66.7300
16:07:15
LSE
1231703
24,227
66.7300
16:08:26
LSE

1234151
7,624
66.7400
16:08:58
LSE
1235074
3,273
66.7400
16:08:58
LSE
1235072
5,198
66.7400
16:08:58
LSE
1235070
3,045
66.7400
16:08:58
LSE
1235068
2,842
66.7400
16:08:58
LSE
1235066
11,514
66.7400
16:08:58
LSE
1235064
85,482
66.7400
16:08:58
LSE
1235062
20,158
66.7300
16:09:11
LSE
1235685
1,004
66.7400
16:09:35
LSE
1236894
18,829
66.7400
16:09:54
LSE
1237727

6,176
66.7400
16:10:00
LSE
1237895
3,345
66.7400
16:10:00
LSE
1237899
13,970
66.7400
16:10:00
LSE
1237897
6,243
66.7300
16:10:27
LSE
1238979
11,827
66.7300
16:10:38
LSE
1239486
1,909
66.7300
16:10:38
LSE
1239484
15,078
66.7300
16:10:38
LSE
1239482
641
66.7300
16:11:13
LSE
1240767
7,991
66.7300
16:11:13
LSE
1240771
7,016
66.7300
16:11:13
LSE
1240769
9,184

66.7300
16:11:13
LSE
1240765
14,702
66.7300
16:11:51
LSE
1242322
3,082
66.7400
16:11:58
LSE
1242622
4,532
66.7400
16:11:58
LSE
1242620
11,111
66.7400
16:11:58
LSE
1242618
38,055
66.7400
16:11:58
LSE
1242616
32,678
66.7400
16:11:58
LSE
1242614
400
66.7400
16:12:31
LSE
1244194
9,142
66.7400
16:12:35
LSE
1244347
14,624
66.7400
16:12:40
LSE
1244559
8,444
66.7400

16:12:40
LSE
1244555
3,639
66.7400
16:12:40
LSE
1244557
4,549
66.7500
16:13:28
LSE
1246616
45,677
66.7500
16:13:28
LSE
1246614
3,296
66.7500
16:13:28
LSE
1246612
14,979
66.7500
16:13:28
LSE
1246610
16,947
66.7500
16:13:28
LSE
1246608
2,721
66.7500
16:13:28
LSE
1246606
2,702
66.7500
16:13:28
LSE
1246604
2,751
66.7500
16:13:28
LSE
1246602
13,937
66.7500
16:13:28

LSE
1246600
9,284
66.7500
16:13:28
LSE
1246598
5,633
66.7400
16:13:32
LSE
1246989
8,898
66.7400
16:13:32
LSE
1246987
16,768
66.7400
16:14:11
LSE
1248811
3,510
66.7400
16:14:11
LSE
1248813
10,179
66.7400
16:14:11
LSE
1248809
12,126
66.7400
16:14:11
LSE
1248807
20,589
66.7300
16:14:23
LSE
1249322
14,689
66.7300
16:14:48
LSE
1250642
2,155
66.7300
16:15:01
LSE

1251278
400
66.7300
16:15:05
LSE
1251435
400
66.7300
16:15:05
LSE
1251433
4,303
66.7100
16:15:09
LSE
1251591
15,000
66.7100
16:15:09
LSE
1251589
12,417
66.7300
16:15:09
LSE
1251587
15,162
66.7300
16:15:09
LSE
1251585
400
66.7300
16:15:09
LSE
1251577
2,511
66.7000
16:15:18
LSE
1252034
7,000
66.7000
16:15:18
LSE
1252032
12,846
66.7000
16:15:18
LSE
1252030

20,460
66.7000
16:15:18
LSE
1252026
4,208
66.6900
16:15:34
LSE
1252706
8,099
66.7000
16:16:06
LSE
1254323
13,767
66.7000
16:16:06
LSE
1254325
646
66.7000
16:16:43
LSE
1256373
61,935
66.7000
16:16:43
LSE
1256371
72,408
66.7000
16:16:43
LSE
1256369
6,070
66.7000
16:16:43
LSE
1256367
6,115
66.7000
16:16:43
LSE
1256365
5,248
66.7000
16:16:53
LSE
1256801
15,400

66.7000
16:16:53
LSE
1256799
19,505
66.6900
16:16:58
LSE
1256992
1,852
66.6900
16:17:55
LSE
1259485
10,271
66.6900
16:17:55
LSE
1259483
7,922
66.6900
16:17:55
LSE
1259481
5,109
66.6900
16:17:55
LSE
1259479
2,778
66.6900
16:17:55
LSE
1259477
1,641
66.6800
16:18:13
LSE
1260361
18,187
66.6800
16:18:13
LSE
1260359
19,840
66.6800
16:18:13
LSE
1260357
23,442
66.6700

16:19:03
LSE
1262834
22,691
66.6600
16:19:06
LSE
1263153
22,464
66.6500
16:19:08
LSE
1263226
38,620
66.6700
16:19:58
LSE
1266093
26,236
66.6700
16:19:58
LSE
1266083
5,538
66.6700
16:19:58
LSE
1266077
8,188
66.6700
16:19:58
LSE
1266079
3,242
66.6700
16:19:58
LSE
1266081
5,648
66.6700
16:19:58
LSE
1266075
3,383
66.6700
16:19:58
LSE
1266085
17,762
66.6700
16:19:58

LSE
1266091
7,143
66.6700
16:19:58
LSE
1266089
2,690
66.6700
16:19:58
LSE
1266087
6,939
66.6700
16:19:58
LSE
1266073
400
66.7500
16:21:59
LSE
1273089
11,968
66.7500
16:22:07
LSE
1273497
17,992
66.7500
16:22:07
LSE
1273495
9,000
66.7500
16:22:07
LSE
1273493
12,312
66.7500
16:22:07
LSE
1273488
11,009
66.7500
16:22:07
LSE
1273486
1,540
66.7500
16:22:07
LSE

1273484
18,311
66.7500
16:22:07
LSE
1273482
13,062
66.7500
16:22:07
LSE
1273480
32,767
66.7500
16:22:23
LSE
1274262
7,800
66.7500
16:22:23
LSE
1274260
1,643
66.7500
16:22:30
LSE
1274511
17,923
66.7500
16:22:30
LSE
1274509
7,000
66.7500
16:22:30
LSE
1274507
22,190
66.7500
16:22:30
LSE
1274503
5,345
66.7500
16:22:30
LSE
1274501
400
66.7400
16:22:58
LSE
1275951

24,422
66.7400
16:22:59
LSE
1276040
25,020
66.7300
16:23:26
LSE
1278042
5,766
66.7300
16:23:43
LSE
1278782
10,770
66.7300
16:23:46
LSE
1278865
4,909
66.7400
16:23:48
LSE
1278965
3,648
66.7400
16:23:48
LSE
1278963
9,300
66.7400
16:23:48
LSE
1278961
23,490
66.7400
16:23:48
LSE
1278949
3,764
66.7400
16:23:48
LSE
1278943
1,429
66.7400
16:23:48
LSE
1278945
3,766

66.7400
16:23:48
LSE
1278947
17,929
66.7400
16:23:48
LSE
1278959
5,987
66.7400
16:23:48
LSE
1278951
9,119
66.7400
16:23:48
LSE
1278953
3,887
66.7400
16:23:48
LSE
1278955
50,655
66.7400
16:23:48
LSE
1278957
6,787
66.7400
16:24:05
LSE
1279927
10,728
66.7400
16:24:08
LSE
1280182
1,484
66.7400
16:24:11
LSE
1280315
2,646
66.7400
16:24:15
LSE
1280527
10,822
66.7400

16:24:18
LSE
1280702
10,224
66.7400
16:24:21
LSE
1280872
255
66.7400
16:24:21
LSE
1280870
2,449
66.7400
16:24:29
LSE
1281409
10,387
66.7400
16:24:29
LSE
1281407
7,528
66.7400
16:24:29
LSE
1281405
6,219
66.7400
16:24:29
LSE
1281403
1,727
66.7400
16:24:29
LSE
1281401
20,088
66.7300
16:24:35
LSE
1282081
6,836
66.7100
16:24:39
LSE
1282281
7,431
66.7100
16:24:40

LSE
1282369
813
66.7100
16:24:45
LSE
1282658
3,256
66.7100
16:24:47
LSE
1282801
5,514
66.7100
16:24:51
LSE
1282989
10,766
66.7100
16:24:51
LSE
1282987
1,548
66.7100
16:24:51
LSE
1282970
2,161
66.7100
16:24:51
LSE
1282968
6,600
66.7100
16:24:53
LSE
1283112
955
66.7100
16:24:53
LSE
1283114
6,960
66.7100
16:24:56
LSE
1283222
778
66.7100
16:24:59
LSE

1283340
4,736
66.7100
16:24:59
LSE
1283338
3,045
66.7100
16:25:04
LSE
1283610
1,715
66.7100
16:25:04
LSE
1283608
7,079
66.7100
16:25:06
LSE
1283710
3,745
66.7100
16:25:10
LSE
1283885
787
66.7100
16:25:10
LSE
1283887
7,405
66.7100
16:25:11
LSE
1283912
757
66.7100
16:25:14
LSE
1283981
4,528
66.7100
16:25:15
LSE
1284016
4
66.7100
16:25:15
LSE
1284014

7,030
66.7100
16:25:17
LSE
1284125
4,805
66.7100
16:25:21
LSE
1284297
2,551
66.7100
16:25:21
LSE
1284295
4,532
66.7100
16:25:21
LSE
1284286
4,532
66.7100
16:25:23
LSE
1284699
838
66.7100
16:25:29
LSE
1284951
4,322
66.7100
16:25:32
LSE
1285085
14,009
66.7100
16:25:32
LSE
1285087
10,912
66.7000
16:25:33
LSE
1285152
5,060
66.7000
16:25:33
LSE
1285137
4,438

66.6900
16:25:34
LSE
1285228
17,399
66.7000
16:25:34
LSE
1285210
4,217
66.7000
16:25:34
LSE
1285208
15,524
66.6900
16:25:38
LSE
1285375
18,953
66.6800
16:25:43
LSE
1285780
6,010
66.6700
16:25:50
LSE
1285977
4,532
66.6700
16:25:54
LSE
1286072
49
66.6700
16:25:56
LSE
1286133
2,597
66.6700
16:25:56
LSE
1286131
781
66.6700
16:25:59
LSE
1286299
7,157
66.6700

16:26:01
LSE
1286471
4,532
66.6700
16:26:05
LSE
1286687
12,428
66.6700
16:26:06
LSE
1286721
1,414
66.6700
16:26:06
LSE
1286719
9,000
66.6600
16:26:08
LSE
1286880
5,261
66.6600
16:26:08
LSE
1286861
9,000
66.6600
16:26:08
LSE
1286859
17,744
66.6600
16:26:08
LSE
1286833
17,415
66.6600
16:26:08
LSE
1286781
5,165
66.6400
16:26:14
LSE
1287285
820
66.6400
16:26:14

LSE
1287283
7,780
66.6400
16:26:15
LSE
1287311
180
66.6400
16:26:18
LSE
1287387
3,239
66.6400
16:26:27
LSE
1287780
9,553
66.6400
16:26:27
LSE
1287776
820
66.6400
16:26:31
LSE
1287961
6,978
66.6400
16:26:31
LSE
1287948
4,532
66.6400
16:26:31
LSE
1287944
6,345
66.6400
16:26:36
LSE
1288119
5,316
66.6400
16:26:37
LSE
1288172
5,492
66.6400
16:26:37
LSE

1288170
7,251
66.6400
16:26:38
LSE
1288184
5,907
66.6400
16:26:40
LSE
1288260
1,746
66.6400
16:26:40
LSE
1288258
5,609
66.6400
16:26:46
LSE
1288552
1,258
66.6400
16:26:50
LSE
1288752
6,423
66.6600
16:27:28
LSE
1290496
8,818
66.6600
16:27:37
LSE
1290821
14,500
66.6600
16:27:38
LSE
1290873
4,169
66.6600
16:27:38
LSE
1290871
9,225
66.6600
16:27:49
LSE
1291339

12,871
66.6600
16:27:49
LSE
1291341
25,272
66.6500
16:28:11
LSE
1292560
41,492
66.6600
16:28:11
LSE
1292465
4,269
66.6300
16:28:15
LSE
1292845
5,149
66.6400
16:28:25
LSE
1293162
9,505
66.6400
16:28:28
LSE
1293266
400
66.6400
16:28:29
LSE
1293297
5,417
66.6400
16:28:29
LSE
1293288
9,246
66.6400
16:28:33
LSE
1293436
4,850
66.6400
16:28:35
LSE
1293671
8,146

66.6400
16:28:39
LSE
1293774
50,356
66.6400
16:28:39
LSE
1293772
9,532
66.6400
16:28:39
LSE
1293770
15,469
66.6500
16:28:40
LSE
1293807
4,532
66.6500
16:28:40
LSE
1293801
15,034
66.6500
16:28:40
LSE
1293805
9,919
66.6500
16:28:40
LSE
1293803
10,724
66.6500
16:28:40
LSE
1293795
28,970
66.6500
16:28:40
LSE
1293793
15,920
66.6500
16:28:40
LSE
1293799
113,033
66.6500

16:28:40
LSE
1293797

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LLOYDS BANKING GROUP plc
(Registrant)

By: Douglas Radcliffe
Name: Douglas Radcliffe
Title: Group Investor Relations Director

Date: 14 May 2018